MedTrace Logo

Aligning Medications With What Matters Most

NCT04938648 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2023-05-26

Study results available
· View outcomes & findings →

Summary

The Aligning Medications with What Matters Most (ALIGN) study will assess the feasibility and preliminary efficacy of a deprescribing intervention to reduce medication regimen complexity and treatment burden for people living with dementia (PLWD) and their care partners.

Conditions

  • Polypharmacy
  • Alzheimer Disease and Related Dementias

Interventions

BEHAVIORAL

Pharmacist-led deprescribing intervention

1\) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP

Sponsors & Collaborators

  • Kaiser Permanente

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Ariel Green, MD, MPH, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-03
Primary Completion
2022-05-02
Completion
2022-05-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938648 on ClinicalTrials.gov